Friday, July 31, 2015

AquaBounty's new fish: Critical risk is to environment

Craig Altier, associate professor at Cornell University's College of Veterinary Medicine and a member of the Food and Drug Administration's Veterinary Medicine Advisory Committee, warns about the high risk of uncertain consequences if a genetically modified organism is accidentally loosed on the environment.

AquaBounty's new fish: Critical risk is to environment

0 comments

Craig Altier, associate professor at Cornell University's College of Veterinary Medicine and a member of the Food and Drug Administration’s Veterinary Medicine Advisory Committee, appears willing to accept the FDA's conclusions on the consumer safety of genetically engineered salmon. But he sides with environmental groups in warning about the high risk of uncertain consequences if a genetically modified organism is accidentally loosed on the environment.  Altier says:

The fisheries of the world are being rapidly depleted and so advances in aquaculture will be needed to meet the growing demand for protein. Genetically engineered animals might help to feed the world, but they must first meet the most stringent requirements for human and environmental safety.

Is the introduced growth hormone gene safe for the fish itself? The studies designed to determine this were flawed, and so we don't know yet whether this is true. The burden of proof here is on the producer of this fish, Aquabounty, to perform further research to establish safety for the fish.

Is the fish safe for human consumption? Exhaustive analysis by the FDA showed no difference from conventional salmon. The growth hormone itself presents no specific risk, as we consume growth hormone in all meats we eat. The FDA also found no increase in allergens, which is important, as fish is already a food that causes allergic reactions in many people.

We advised the FDA on the possible environmental impacts of this fish. Containment of the fish is essential, as the release of this fast-growing animal could have devastating effects on native fish populations. The producer, AquaBounty, plans to raise these fish in an inland, self-contained facility. To protect wild fish stocks, these facilities would require the utmost security, rigorous inspections and constant oversight by the FDA.

We need to treat these fish as we would a potentially dangerous medicine or pharmaceutical, and apply all of the same security measures to its production and transport.

Food for thought as the FDA weighs the potential risks and benefits of any genetically modified products.

 

 

 

 

Inquirer Business Columnist
0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog

Jeff Gelles, who writes the Inquirer's weekly Consumer 14.0 and Tech Life columns, takes a broad look at the marketplace of goods, services, and ideas.

Reach Jeff at jgelles@phillynews.com.

Jeff Gelles Inquirer Business Columnist
Also on Philly.com:
letter icon Newsletter